DE19732334T1 - Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon - Google Patents
Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon Download PDFInfo
- Publication number
- DE19732334T1 DE19732334T1 DE19732334.8T DE19732334T DE19732334T1 DE 19732334 T1 DE19732334 T1 DE 19732334T1 DE 19732334 T DE19732334 T DE 19732334T DE 19732334 T1 DE19732334 T1 DE 19732334T1
- Authority
- DE
- Germany
- Prior art keywords
- site
- pharmaceutical composition
- bacterial
- pac
- cos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract 21
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 16
- 241000700605 Viruses Species 0.000 claims abstract 8
- 238000004806 packaging method and process Methods 0.000 claims abstract 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 4
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 4
- 241000894006 Bacteria Species 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 108091028732 Concatemer Proteins 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 4
- 108091033409 CRISPR Proteins 0.000 claims 3
- 101710163270 Nuclease Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 108020005004 Guide RNA Proteins 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 102220560681 ATP-binding cassette sub-family C member 8_F27S_mutation Human genes 0.000 claims 1
- 101100214874 Autographa californica nuclear polyhedrosis virus AC81 gene Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102220511796 F-actin-capping protein subunit beta_F26S_mutation Human genes 0.000 claims 1
- 208000026680 Metabolic Brain disease Diseases 0.000 claims 1
- 101000740206 Mus musculus Sal-like protein 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 102100037205 Sal-like protein 2 Human genes 0.000 claims 1
- 101710192308 Sal-like protein 2 Proteins 0.000 claims 1
- 101100465903 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psp3 gene Proteins 0.000 claims 1
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 claims 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims 1
- 238000010459 TALEN Methods 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000003214 anti-biofilm Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 239000000304 virulence factor Substances 0.000 claims 1
- 230000007923 virulence factor Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
- C12N2795/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10141—Use of virus, viral particle or viral elements as a vector
- C12N2795/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10341—Use of virus, viral particle or viral elements as a vector
- C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/202—Pseudochromosomes, minichrosomosomes of bacteriophage origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Pharmazeutische Zusammensetzung, umfassend mindestens zwei verschiedene bakterielle Überbringungsvehikel, in die die gleiche Nutzlast verpackt ist, wobei die Nutzlast umfasst:- eine interessierende Nukleinsäuresequenz unter der Kontrolle eines Promotors; und- mindestens zwei orthogonale bakterielle Virusverpackungsstellen, die das Verpacken in die mindestens zwei verschiedenen bakteriellen Überbringungsvehikel ermöglichen.
Claims (15)
- Pharmazeutische Zusammensetzung, umfassend mindestens zwei verschiedene bakterielle Überbringungsvehikel, in die die gleiche Nutzlast verpackt ist, wobei die Nutzlast umfasst: - eine interessierende Nukleinsäuresequenz unter der Kontrolle eines Promotors; und - mindestens zwei orthogonale bakterielle Virusverpackungsstellen, die das Verpacken in die mindestens zwei verschiedenen bakteriellen Überbringungsvehikel ermöglichen.
- Pharmazeutische Zusammensetzung nach
Anspruch 1 , wobei die mindestens zwei orthogonalen bakteriellen Virusverpackungsstellen mindestens zwei verschiedene cos-Stellen, mindestens zwei verschiedene pac-Stellen oder mindestens zwei verschiedene Concatemer-Verbindungsstellen sind, oder, die mindestens zwei orthogonalen bakteriellen Virusverpackungsstellen mindestens eine cos-Stelle und mindestens eine pac-Stelle, mindestens eine cos-Stelle und mindestens eine Concatemer-Verbindungsstelle, mindestens eine pac-Stelle und mindestens eine Concatemer-Verbindungsstelle, oder mindestens eine cos-Stelle, mindestens eine pac-Stelle und mindestens eine Concatemer-Verbindungsstelle sind. - Pharmazeutische Zusammensetzung nach
Anspruch 1 oder2 , wobei die mindestens zwei orthogonalen bakteriellen Virusverpackungsstellen ausgewählt sind in der Gruppe bestehend aus λ cos-Stelle, P4 cos-Stelle, SPP1 pac-Stelle, P1 pac-Stelle, T1 pac-Stelle, mu pac-Stelle, P22 pac-Stelle, ϕ8 pac-Stelle, Sf6 pac-Stelle, 149 pac-Stelle, T7-Concatemer-Verbindung, Al 122-Concatemer-Verbindung, vorzugsweise die mindestens zwei orthogonalen bakteriellen Virusverpackungsstellen umfassend λ cos-Stelle und P4 cos-Stelle, oder λ cos-Stelle, P4 cos-Stelle und P1 pac-Stelle, oder λ cos-Stelle, P4 cos-Stelle und T7-Concatemer-Verbindung oder λ cos-Stelle, P4 cos-Stelle, P1 pac-Stelle und T7-Concatemer-Verbindung. - Pharmazeutische Zusammensetzung nach einem der
Ansprüche 1 -3 , wobei die interessierende Nukleinsäuresequenz ausgewählt ist aus der Gruppe bestehend aus einer Cas-Nuklease, einer Cas9-Nuklease, einer Leit-RNA, einer Einzelleit-RNA (sgRNA), einem CRISPR-Locus, einem Toxin, einem Gen, das ein Enzym wie beispielsweise eine Nuklease oder eine Kinase exprimiert, einer TALEN, einer ZFN, einer Meganuklease, einer Rekombinase, einem bakteriellen Rezeptor, einem Membranprotein, einem Strukturprotein, einem sezernierten Protein, einem Gen, das eine Resistenz gegen ein Antibiotikum oder gegen einen Arzneistoff im Allgemeinen exprimiert, einem Gen, das ein toxisches Protein oder einen toxischen Faktor exprimiert, und einem Gen, das ein Virulenzprotein oder einen Virulenzfaktor oder eine Kombination davon exprimiert. - Pharmazeutische Zusammensetzung nach
Anspruch 1 -4 , wobei die interessierende Nukleinsäuresequenz ein Cas9-System zur Reduktion der Genexpression oder Inaktivierung eines Gens ist, das ausgewählt ist in der Gruppe bestehend aus einem Antibiotikaresistenzgen, einem Virulenzfaktor- oder Proteingen, einem Toxinfaktor- oder Proteingen, einem Gen, das einen bakteriellen Rezeptor, ein Membranprotein, ein Strukturprotein, ein sezerniertes Protein exprimiert und einem Arzneimittelresistenzgen oder jeder Kombination davon. - Pharmazeutische Zusammensetzung nach einem der
Ansprüche 1 -5 , wobei die bakteriellen Überbringungsvehikel bakterielle Viren sind, vorzugsweise bakterielle Viren, die ausgewählt sind aus der Liste bestehend aus BW73, B278, D6, D108, E, EI, E24, E41, FI-2, FI-4, FI-5, HI8A, Ffl8B, i, MM, Mu, 025, Phl-5, Pk, PSP3, PI, PID, P2, P4, SI, Wϕ, ϕK13, ϕ1, ϕ2, ϕ7, ϕ92, 7 A, 8ϕ, 9ϕ, 18, 28-1, 186, 299, HH-Escherichia (2), AB48, CM, C4, C16, DD-VI, E4, E7, E28, FII, FI3, H, HI, H3, H8, K3, M, N, ND-2, ND-3, ND4, ND-5, ND6, ND-7, Ox-1, Ox-2, Ox-3, Ox-4, Ox-5, Ox-6, Phl-I, RB42, RB43, RB49, RB69, S, Sal-I, Sal-2, Sal-3, Sal-4, Sal-5, Sal-6, TC23, TC45, Tull*-6, TulP-24, Tull*46, TulP-60, T2, T4, T6, T35, αl, 1, IA, 3, 3A, 3T+, 5ϕ, 9266Q, CF0103, HK620, J, K, KIF, m59, Nr. A, Nr. E, Nr. 3, Nr. 9, N4, sd, T3, T7, WPK, W31, ΔH, ϕC3888, ϕK3, ϕK7, ϕK12, ϕV-1, Φ04-CF, Φ05, Φ06, Φ07, ϕI, ϕI.2, ϕ20, ϕ95, ϕ263, ϕI092, ΦI, ΦII, Ω8,1,3, 7, 8, 26, 27, 28-2, 29, 30, 31, 32, 38, 39, 42, 933W, NN-Escherichia (1), Esc-7-11, AC30, CVX-5, CI, DDUP, ECI, EC2, E21, E29, FI, F26S, F27S, Hi, HK022, HK97, HK139, HK253, HK256, K7, ND-I, PA-2, q, S2, TI, ), T3C, T5, UC-I, w, β4, y2, λ, ΦD326, Φy, Φ06, Φ7, Φ10, Φ80, χ, 2, 4, 4A, 6, 8A, 102, 150, 168, 174, 3000, AC6, AC7, AC28, AC43, AC50, AC57, AC81, AC95, HK243, KIO, ZG/3A, 5, 5A, 21EL, H19-J und 933H. - Pharmazeutische Zusammensetzung nach einem der
Ansprüche 1 -6 , wobei die bakteriellen Überbringungsvehikel in der Lage sind, auf mindestens zwei verschiedene Bakterien abzuzielen und die Nutzlast in die mindestens zwei verschiedenen Bakterien einzubringen. - Pharmazeutische Zusammensetzung nach einem der
Ansprüche 1 -7 , wobei die bakteriellen Überbringungsvehikel in der Lage sind, auf das gleiche Bakterium abzuzielen und die Nutzlast in das Bakterium einzubringen. - Pharmazeutische Zusammensetzung nach einem der
Ansprüche 1 -8 , wobei die pharmazeutische Zusammensetzung ferner mindestens einen zusätzlichen Wirkstoff, beispielsweise ein Präbiotikum und/oder ein Probiotikum und/oder ein Antibiotikum, und/oder ein weiteres antibakterielles oder Antibiofilm-Mittel, und/oder ein Mittel, das die Zielgenauigkeit der bakteriellen Überbringungsvehikel auf die Bakterien und/oder die Überbringung der Nutzlast in die Bakterien verstärkt, oder jede Kombination davon, umfasst. - Pharmazeutische Zusammensetzung nach einem der
Ansprüche 1 -9 , zur Verwendung als Arzneimittel. - Pharmazeutische Zusammensetzung zur Verwendung nach
Anspruch 10 , zur in-situ bakteriellen Produktion einer interessierenden Verbindung, vorzugsweise wobei die interessierende Verbindung im Inneren der Zielbakterien produziert, von den Zielbakterien sezerniert oder auf der Oberfläche der Zielbakterien exprimiert wird. - Pharmazeutische Zusammensetzung zur Verwendung nach
Anspruch 11 , wobei die interessierende Verbindung ein Antigen ist, das auf der Oberfläche der Zielbakterien zur prophylaktischen und/oder therapeutischen Impfung exprimiert wird. - Pharmazeutische Zusammensetzung nach den
Ansprüchen 1 -9 oder pharmazeutische Zusammensetzung zur Verwendung nach denAnsprüchen 10 -12 , zur Verwendung bei der Behandlung einer Störung oder Erkrankung, die durch ein Bakterium, vorzugsweise durch ein antibiotikaresistentes Bakterium, verursacht wird, wie beispielsweise eine Infektion, vorzugsweise eine bakterielle Infektion, entzündliche Erkrankungen, Autoimmunerkrankungen, Krebs, metabolische Störungen und/oder Gehirnerkrankungen. - Nutzlast wie in einem der
Ansprüche 1 -5 definiert. - Bakterielles Überbringungsvehikel, umfassend die Nutzlast nach
Anspruch 14 .
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305781.9A EP3584316B1 (de) | 2018-06-20 | 2018-06-20 | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
EP18305781 | 2018-06-20 | ||
PCT/EP2019/066104 WO2019243373A1 (en) | 2018-06-20 | 2019-06-18 | Bacterial delivery vehicle, process of production and uses thereof |
EP19732334.8A EP3810765A1 (de) | 2018-06-20 | 2019-06-18 | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19732334T1 true DE19732334T1 (de) | 2021-09-30 |
Family
ID=62909472
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE18305781.9T Pending DE18305781T1 (de) | 2018-06-20 | 2018-06-20 | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
DE19732334.8T Pending DE19732334T1 (de) | 2018-06-20 | 2019-06-18 | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE18305781.9T Pending DE18305781T1 (de) | 2018-06-20 | 2018-06-20 | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
Country Status (5)
Country | Link |
---|---|
US (3) | US11124776B2 (de) |
EP (2) | EP3584316B1 (de) |
DE (2) | DE18305781T1 (de) |
DK (2) | DK3584316T1 (de) |
WO (1) | WO2019243373A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3584316B1 (de) | 2018-06-20 | 2024-04-03 | Eligo Bioscience | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
WO2020237044A1 (en) * | 2019-05-21 | 2020-11-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bacteriophages for the treatment of tuberculosis |
CN114502748A (zh) * | 2019-06-18 | 2022-05-13 | 艾力格生物科技有限公司 | 包含示踪核酸序列的细菌递送媒介物 |
EP4256037A1 (de) * | 2021-10-01 | 2023-10-11 | ETH Zürich | Heterologe bacteriocine produzierende bakteriophagen |
CN114574467B (zh) * | 2022-01-21 | 2023-05-23 | 华南农业大学 | 一种基因表达调控系统及其应用 |
US20230233299A1 (en) * | 2022-01-27 | 2023-07-27 | EdgeEndo, LLC | Dental, endodontic, and periodontic treatment methods and systems |
WO2023212396A1 (en) * | 2022-04-29 | 2023-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | High capacity lentiviral vectors |
WO2024003301A1 (en) * | 2022-06-29 | 2024-01-04 | Snipr Biome Aps | Targeting e coli cells |
GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
WO2024194876A1 (en) * | 2023-03-23 | 2024-09-26 | Technion Research & Development Foundation Limited | Bacteriophages as a tool to manipulate gut commensal immune-modulation activity |
CN116676324B (zh) * | 2023-07-28 | 2023-10-27 | 四川大学华西医院 | 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK594084A (da) | 1984-12-12 | 1986-06-13 | Novo Industri As | Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning |
US6566121B1 (en) | 1991-06-13 | 2003-05-20 | Albert Einstein College Of Medicine Of Yeshiva University | Insertional mutations in mycobacteria |
US5691185A (en) | 1993-10-08 | 1997-11-25 | Chr. Hansen A/S | Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria |
US6291245B1 (en) | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
US6413768B1 (en) | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
GB0611484D0 (en) * | 2006-06-09 | 2006-07-19 | Sinvent As | Plasmid RK2-based broad-host-range cloning vector useful for transfer of metagenomic libraries to a variety of bacterial species |
JP2010529862A (ja) * | 2007-06-16 | 2010-09-02 | スカラブ ゲノミクス, エルエルシー | 核酸パッケージングシステム |
US10660943B2 (en) | 2013-02-07 | 2020-05-26 | The Rockefeller University | Sequence specific antimicrobials |
EP4074330A1 (de) | 2013-09-05 | 2022-10-19 | Massachusetts Institute of Technology | Abstimmung von mikrobiellen populationen mit programmierbaren nukleasen |
EP3584316B1 (de) | 2018-06-20 | 2024-04-03 | Eligo Bioscience | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon |
-
2018
- 2018-06-20 EP EP18305781.9A patent/EP3584316B1/de active Active
- 2018-06-20 DK DK18305781.9T patent/DK3584316T1/da unknown
- 2018-06-20 DE DE18305781.9T patent/DE18305781T1/de active Pending
-
2019
- 2019-06-18 DK DK19732334.8T patent/DK3810765T1/da unknown
- 2019-06-18 US US16/444,576 patent/US11124776B2/en active Active
- 2019-06-18 DE DE19732334.8T patent/DE19732334T1/de active Pending
- 2019-06-18 EP EP19732334.8A patent/EP3810765A1/de active Pending
- 2019-06-18 WO PCT/EP2019/066104 patent/WO2019243373A1/en unknown
-
2021
- 2021-08-19 US US17/406,437 patent/US11952594B2/en active Active
-
2024
- 2024-03-07 US US18/598,495 patent/US20240209326A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3810765A1 (de) | 2021-04-28 |
DK3584316T1 (da) | 2020-08-03 |
DK3810765T1 (da) | 2021-08-23 |
US20210380953A1 (en) | 2021-12-09 |
EP3584316B1 (de) | 2024-04-03 |
US20240209326A1 (en) | 2024-06-27 |
EP3584316A1 (de) | 2019-12-25 |
US11952594B2 (en) | 2024-04-09 |
US11124776B2 (en) | 2021-09-21 |
US20190390175A1 (en) | 2019-12-26 |
DE18305781T1 (de) | 2020-09-17 |
WO2019243373A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19732334T1 (de) | Bakterielles freisetzungsvehikel, verfahren zur herstellung und verwendungen davon | |
Kocabey et al. | Cellular uptake of tile-assembled DNA nanotubes | |
Swetha et al. | Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines | |
WO2002085434A1 (de) | Injektionsgerät für rna applikation | |
EP3246403A3 (de) | Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna-bindungsaffinität | |
DE112006003608T5 (de) | Verfahren zur Präsentation von Zielproteinen an der Zelloberfläche unter Verwendung von Bacillus Anthracis-Exosporium | |
Azam et al. | Bacteriophage technology and modern medicine | |
Kurimoto et al. | PEG-OligoRNA hybridization of mRNA for developing sterically stable lipid nanoparticles toward in vivo administration | |
Lin et al. | Co-delivery of imiquimod and plasmid DNA via an amphiphilic pH-responsive star polymer that forms unimolecular micelles in water | |
CA2386536A1 (en) | Methods for treating muscular dystrophy with bone marrow cells | |
Kim et al. | Efficient delivery of plasmid DNA using cholesterol-based cationic lipids containing polyamines and ether linkages | |
Kanu et al. | Gold nanoparticle-mediated gene therapy | |
Ghodhbane-Gtari et al. | Ecology and physiology of non-Frankia Actinobacteria from actinorhizal plants | |
Chongchai et al. | Targeting human osteoarthritic chondrocytes with ligand directed bacteriophage-based particles | |
JP2016020489A5 (de) | ||
Mir et al. | The mRNA vaccine, a swift warhead against a moving infectious disease target | |
Hu et al. | Synthesis of mannosylated polyethylenimine and its potential application as cell-targeting non-viral vector for gene therapy | |
De Giglio et al. | Solid Lipid Nanoparticles Containing Dopamine and Grape Seed Extract: Freeze-Drying with Cryoprotection as a Formulation Strategy to Achieve Nasal Powders | |
Chang et al. | Gene therapy using efficient direct lineage reprogramming technology for neurological diseases | |
EP2190982B1 (de) | System, umfassend wirkstoffe umfassende partikel und bakteriophagen | |
DE69427188T2 (de) | Zusammensetzung zur behandlung von tumoren und immunisierung von organismen gegen tumore | |
Kim et al. | Intravenous administration of heat shock-treated MSCs can improve neuroprotection and neuroregeneration in canine spinal cord injury model | |
Niazi | The Dawn of In Vivo Gene Editing Era: A Revolution in the Making | |
DE10016881A1 (de) | Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer | |
WO2021159129A3 (en) | Compositions and methods for circular rna expression |